Hpv vaccination: Too soon for 2 doses?
Mené au Canada auprès de 830 participantes sur la période 2007-2011, cet essai de non infériorité de phase III compare, du point de vue des niveaux sanguins d'anticorps anti papillomavirus humain de type 16 et anti papillomavirus humain de type 18, l'efficacité de deux et trois doses de vaccin quadrivalent contre une infection par le virus HPV en fonction de la catégorie d'âge des participantes (9-13 ans ou 16-26 ans)
Cervical cancer is the second most common cancer among women globally, according to age-standardized incidence rates.1 Approximately 530 000 women are diagnosed with cervical cancer and 275 000 die of the disease every year; 88% of deaths occur in developing regions of the world.1 Human papillomavirus (HPV) infection is a well-established cause of cervical cancer as well as other anogenital and oropharyngeal cancers; therefore, prophylactic HPV vaccines have the potential to substantially reduce the incidence of cervical cancer and other HPV-associated diseases.2 Three-dose schedules of the bivalent vaccine (HPV-16 and -18) and the quadrivalent vaccine (HPV-6, -11, -16, and -18) have been shown to be highly efficacious in preventing persistent infection with HPV-16 and -18, which cause approximately 70% of cervical cancers, as well as precancerous lesions associated with these types.3- 5 The quadrivalent vaccine has also been shown to prevent anogenital warts associated with HPV-6 and -11.3,5
JAMA , éditorial, 2012